Full Press Release Details
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
| EVENT: | TD Cowen 46th Annual Health Care Conference |
| DATE: | Wednesday, March 4, 2026 |
| TIME: | 9:10am ET |
| WEBCAST: | https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7 |
| EVENT: | Leerink Partners 2026 Global Healthcare Conference |
| DATE: | Monday, March 9, 2026 |
| WEBCAST: | No webcast |
| EVENT: | Jefferies 2026 Biotech on the Beach |
| DATE: | Tuesday, March 10, 2026 |
| DETAILS: | 1x1’s with management; please contact your Jefferies sales representative to schedule a meeting. |
The live and archived webcast for the Cowen event will be accessible from the Company’s website athttps://brightmindsbio.com/investors/under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.